AUTL:NSD-Autolus Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 12.77

Change

0.00 (0.00)%

Market Cap

USD 0.65B

Volume

0.05M

Average Target Price

USD 26.40 (+106.73%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

N/A

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

N/A

USD32.18B N/A N/A
MRNA Moderna, Inc

N/A

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

N/A

USD24.87B N/A N/A
RPRX Royalty Pharma plc

N/A

USD24.33B 36.15 9.83
GMAB Genmab A/S

N/A

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

N/A

USD19.73B N/A N/A
INCY Incyte Corporation

N/A

USD18.93B 47.64 35.20

ETFs Containing AUTL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.26% 50% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.26% 50% F 55% F
Trailing 12 Months  
Capital Gain 6.42% 44% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.42% 44% F 62% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -23.67% N/A N/A 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.67% N/A N/A 8% F
Risk Return Profile  
Volatility (Standard Deviation) 32.45% N/A N/A 43% F
Risk Adjusted Return -72.92% N/A N/A 8% F
Market Capitalization 0.65B 70% C- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.56 68% D+ 44% F
Price / Cash Flow Ratio -6.40 56% F 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -29.62% 82% B- 32% F
Return on Invested Capital -52.02% 60% D- 18% F
Return on Assets -22.28% 64% D 18% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.13 50% F 40% F
Short Percent N/A N/A N/A N/A N/A
Beta 1.95 28% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector